Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2005-11-08
2005-11-08
Navarro, Mark (Department: 1645)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S332000, C435S340000, C435S346000
Reexamination Certificate
active
06962813
ABSTRACT:
The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically toP. aeruginosamucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy ofP. aeruginosainfection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains ofP. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
REFERENCES:
patent: 4578458 (1986-03-01), Pier
patent: 5055455 (1991-10-01), Pier
patent: 5233024 (1993-08-01), Schreiber et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5407796 (1995-04-01), Cutting et al.
patent: 5434086 (1995-07-01), Collins et al.
patent: 5502039 (1996-03-01), Pier
patent: 5980910 (1999-11-01), Pier
patent: 6245735 (2001-06-01), Pier
patent: 6399066 (2002-06-01), Pier
patent: 2004/0091494 (2004-05-01), Pier
patent: WO91/02796 (1991-03-01), None
patent: WO92/18162 (1992-10-01), None
patent: WO93/12240 (1993-06-01), None
patent: WO93/17040 (1993-09-01), None
patent: WO93/24641 (1993-12-01), None
patent: WO94/04669 (1994-03-01), None
patent: WO94/04671 (1994-03-01), None
patent: WO 94/08617 (1994-04-01), None
patent: WO94/25607 (1994-11-01), None
patent: WO95/06743 (1995-03-01), None
patent: WO95/13365 (1995-05-01), None
patent: WO95/25796 (1995-09-01), None
patent: WO95/28494 (1995-10-01), None
Mai et al (Infection and Immunity vol. 61, No. 2, pp. 559-564, Feb. 1993).
Albus et al., Increased levels of IgG subclases specific forPseudomonas aeruginosaexoenzyme and polysaccharide antigens in chronically infected patients with cystic fibrosis. APMIS. Dec. 1989;97(12):1146-8.
DesJardins et al., Abstracts from the annual meeting, Am Soc Microbiol. 1989; p. 49 (abstract B-110).
Garner et al., Immunogenic properties ofPseudomonas aeruginosamucoid exopolysaccharide. Infect Immun. Jun. 1990;58(6):1835-42.
Irvin et al., Immunochemical examination of thePseudomonas aeruginosaglycocalyx: a monoclonal antibody which recognizes L-guluronic acid residues of alginic acid. Can J Microbiol. Mar. 1985;31(3):268-75.
Johansen et al., Experimental immunization withPseudomonas aeruginosaalginate induces IgA and IgG antibody responses. APMIS Dec. 1991;99(12):1061-8.
Mai et al., Inhibition of adherence of mucoidPseudomonas aeruginosaby alginase, specific monoclonal antibodies, and antibiotics. Infect Immun. Oct. 1993;61(10):4338-48.
Meluleni et al., 94th General Meeting of the American Society for Microbiology, Las Vegas, Nevada, May 23-27, 1994. Abst Annu Meet Am Soc Microbiol. May 1994; 94(10): 160.
Pier et al., Analysis of naturally occurring antibodies to mucoidPseudomonas aeruginosain cystic fibrosis patients. J Infect Dis. Feb. 1996;173(2):513-5.
Pier et al., Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody toPseudomonas aeruginosa. J Clin Invest. Mar. 1993;91(3):1079-87.
Pier et al., Vaccine potential ofPseudomonas aeruginosamucoid exopolysaccharide (alginate). Antibiot Chemother. 1991;44:136-42. Review.
Pressler et al., Immunoglobulin allotypes and IgG subclass antibody response toPseudomonas aeruginosaantigens in chronically infected cystic fibrosis patients. Clin Exp Immunol. Nov. 1992;90(2):209-14.
Saunders et al., 86th Annual Meeting of the American Society for Microbiology, Washington, D.C., Mar. 23-28, 1986. Abst Annu Meet Am Soc Microbiol. Mar. 1986; 86(0): 45.
Theilacker et al., Construction and characterization of aPseudomonas aeruginosamucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun. Jul. 2003;71(7):3875-84.
Tosi et al., Cross-sectional and longitudinal studies of naturally occurring antibodies toPseudomonas aeruginosain cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection. J Infect Dis. Aug. 1995;172(2):453-61.
Pier et al., “Complement deposition by antibodies toPseudomonas aeruginosamucoid exopolysaccharide (MEP) and by non-MEP specific opsonins”,J. Immunology, 147: 1869-1876, 1991.
Schreiber et al., “Induction of opsonic antibodies toPseudomonas aeruginosamucoid exopolysaccharide by an anti-idiotype monoclonal antibody”,Journal of Infectious Diseases, 164: 507-514, 1991.
Parad et al., Pulmonary outcome of cystic fibrosis is influenced primarily by mucoidPseudomonas aeruginosainfection and immune status and only modestly by genotype,Infection and Immunity, 67: 4744-4750; 1999.
Meluleni, et al., “MucoidPseudomonas aeruginosagrowing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients”,J. Immunology, 155(4): 2029-38; 1995.
Preston et al., “Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific forPseudomonas aeruginosaserogroup O6 lipopolysaccharide”,Infection and Immunity, 66(9): 4137-4142, 1998.
Preston et al., “Prophylactic and therapeutic efficacy of immunoglobulin G antibodies toPseudomonas aeruginosalipopolysaccharide against murine experimental corneal infection”,Investigation Ophthalmology and Visual Science, 38(7): 1418-1425, 1997. Abstract Only.
Pollack et al., “Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies toPseudomonas aeruginosalipopolysaccharide”,Infection and Immunity, 63(11): 4481-4488, 1995.
Boucher, R et al., “Gene Therapy for Cystic Fibrosis Using E1-Deleted Adenovirus: A Phase I Trial in the Nasal Cavity”,Human Gene Therapy, 1994, 5:615-639.
Boyer, D et al., Poster Presentation. American Thoracic Society, #D33, May 17, 2002.
Cheng, KH et al., “Immunoglobulin A antibodies againstPseudomonas aeruginosain the tear fluid of contact lens wearers”,Invest Ophthalmol Vis SciSep. 1996;37 (10): 2081-8.
Ciofu, O et al., “Avidity of anti-Paeruginosaantibodies during chronic infection in patients with cystic fibrosis”,Thorax1999; 54: 141-144.
Davies, J et al., “Reduction in the adherence ofPseudomonas aeruginosato native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition”,Eur Respir J. Mar. 1999; 13(3): 565-70.
DE Kievit, T et al., “Monoclonal Antibodies That Distinguish Inner Core, Outer Core, and Lipid A Regions ofPseudomonas aeruginosaLipopolysaccharide”, Journal of Bacteriology, Dec. 1994, p. 7129-7139.
Imundo, L. et al, “Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface”,Proc. Natl. Acad. Sci. USA, vol. 92 pp. 3019-3032, Mar. 1995.
Kropinski, A et al., “The extraction and analysis of lipopolysaccharides fromPseudomonas aeruginosastrain PAO, and three rough mutants”,Can. J. Microbiol., 1979, 25: 390-398.
Masoud, H et al., “General Strategy for Structural Analysis of the Oligosaccharide Region of Lipooligosaccharides. Structure of the Oligosaccharide Component ofPseudomonas aeruginosaIATS Serotype 06 Mutant R5 Rough-Type Lipopolysaccharide”,Biochemistry1994, 33, 10568-10578.
Masoud, H et al., “Structural Elucidation of the Lipopolysaccharide Core Region of the O-Chain-Deficient Mutant Strain A28 fromPseudomonas aeruginosaSerotype 06 (International Antigenic Typing Scheme)”,Journal of Bacteriology, Dec. 1995, p. 6718-6726.
Meluleni, G et al., “MucoidPseudomonas aeruginosaGrowing in a Biofilm In Vitro Are Killed by Opsonic Antibodies to the Mucoid Exopolysaccharide Capsule but Not by Antibodies Produced During Chronic Fibrosis Patients”,Journal of Immunology, 1995, 155: 2029-2038.
Middleton, P.G. et al., “Nasal application of the cationic liposome DC-Choi:DOPE does not alter ion transpo
Cavacini Lisa
Pier Gerald B.
Posner Marshall
Preston Michael J.
Beth Israel Deaconess Medical Center Inc.
Navarro Mark
The Brigham and Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
LandOfFree
P. aeruginosa mucoid exopolysaccharide specific binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P. aeruginosa mucoid exopolysaccharide specific binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P. aeruginosa mucoid exopolysaccharide specific binding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3516402